5T4 Antigen in Renal Cell Carcinoma: A Target for Immunotherapy
Author Information
Author(s): Griffiths R W, Gilham D E, Dangoor A, Ramani V, Clarke N W, Stern P L, Hawkins R E
Primary Institution: Paterson Institute for Cancer Research, Christie Research Centre, Manchester, UK
Hypothesis
Can T cells from renal cell carcinoma patients be genetically modified to target and kill 5T4 expressing renal cancer cells?
Conclusion
The study found that the 5T4 oncofoetal antigen is highly expressed in renal cell carcinoma, making it a promising target for immunotherapy.
Supporting Evidence
- 95% of renal cell carcinoma samples showed at least focal positivity for 5T4.
- 15 out of 20 samples exhibited strong positive staining for 5T4.
- T cells genetically modified to express a chimeric receptor targeting 5T4 showed enhanced killing of renal cancer cell lines.
Takeaway
Doctors are looking at a special protein called 5T4 that is found in kidney cancer to help create new treatments that can make the body's immune system fight the cancer better.
Methodology
The study used immunohistochemistry to evaluate 5T4 expression in renal cell carcinoma specimens and tested the ability of genetically modified T cells to kill 5T4-expressing renal cancer cell lines.
Limitations
The study had a small sample size and did not correlate 5T4 expression with prognosis or histological grade.
Participant Demographics
The study included 20 patients with renal cell carcinoma, with a mix of primary and metastatic cases.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website